Laura Tadvalkar
Director/Board Member at CIDARA THERAPEUTICS, INC.
Profile
Laura Tadvalkar is currently a Director at Expansion Therapeutics, Inc., Hemab ApS, Aliada Therapeutics, Inc., and Cidara Therapeutics, Inc. She is also a Principal at RA Capital Management LP (Private Equity).
Ms. Tadvalkar holds a doctorate degree from Harvard University, which she obtained in 2014.
She also completed her undergraduate studies at Yale University in 2009.
Laura Tadvalkar active positions
| Companies | Position | Start |
|---|---|---|
| CIDARA THERAPEUTICS, INC. | Director/Board Member | 2024-04-23 |
Hemab ApS
 Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Director/Board Member | 2021-07-21 |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Corporate Officer/Principal | 2020-11-30 |
Expansion Therapeutics, Inc.
 Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | Director/Board Member | 2020-12-31 |
Aliada Therapeutics, Inc.
 Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Director/Board Member | - |
Training of Laura Tadvalkar
| Yale University | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| CIDARA THERAPEUTICS, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Hemab ApS
Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Expansion Therapeutics, Inc.
Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA. | Health Technology |
Aliada Therapeutics, Inc.
Aliada Therapeutics, Inc. BiotechnologyHealth Technology Aliada Therapeutics, Inc. is a neuroscience-focused company that aims to overcome the delivery hurdle in large molecule drug development. The company is based in Boston, MA. The company is advancing a generation of CNS therapeutics using its novel BBB crossing platform technology, which can efficiently transport a diverse array of therapeutic cargoes into the brain, resulting in enhanced downstream effectiveness. Aliada Therapeutics was founded by Sanjaya Singh, and the CEO is Adam Rosenberg. | Health Technology |
- Stock Market
- Insiders
- Laura Tadvalkar